Farther Finance Advisors LLC Decreases Stake in Solventum Co. (NYSE:SOLV)

Farther Finance Advisors LLC reduced its holdings in Solventum Co. (NYSE:SOLV) by 27.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 757 shares of the company’s stock after selling 289 shares during the period. Farther Finance Advisors LLC’s holdings in Solventum were worth $50,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Modus Advisors LLC purchased a new position in shares of Solventum in the fourth quarter worth about $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum in the fourth quarter worth about $26,000. Crews Bank & Trust purchased a new position in shares of Solventum in the fourth quarter worth about $32,000. True Wealth Design LLC lifted its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after buying an additional 471 shares in the last quarter. Finally, Synergy Asset Management LLC purchased a new position in shares of Solventum in the fourth quarter worth about $35,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley raised their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Finally, Piper Sandler raised their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Solventum presently has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Price Performance

Shares of SOLV opened at $74.00 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The stock has a market cap of $12.80 billion and a PE ratio of 26.91. The firm has a 50-day simple moving average of $75.17 and a two-hundred day simple moving average of $71.61. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.